AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) — Aspira Girls’s Well being Inc. (“Aspira”), a bio-analytical based mostly girls’s well being firm centered on gynecologic illness, right this moment introduced that it’s going to host a key opinion chief (KOL) webinar on girls’s well being and ovarian most cancers danger assessments using multivariant index assays on Wednesday, August 24, 2022 at 12:00pm Japanese Time.
This occasion will probably be hosted by Aspira Girls’s Well being executives Nicole Sandford, CEO, Dr. Ryan Phan, PhD, Chief Scientific Officer/Chief Working Officer, and Dr. Charles Dunton, MD, Chief Medical Officer and can characteristic shows from KOLs Nicole E. Williams, MD, FACOG, FACS, Founder and CEO of The Gynecology Institute of Chicago, and Gerard P. Reilly, MD, Director of Scientific Analysis and Innovation, Axia Girls’s Well being.
Dr. Williams will focus on how Aspira’s OVA1Plus® check results in improved well being outcomes for girls with adnexal plenty by serving to physicians to stratify sufferers deliberate for surgical procedure based mostly on their danger of ovarian most cancers. OVA1Plus is a mix of two FDA-cleared multivariate index assays that mixes the outcomes of biomarkers and proprietary algorithms to offer a malignancy danger index to physicians.
Dr. Reilly was a co-author of a lately printed paper, Analytical Validation of a Deep Neural Community Algorithm for the Detection of Ovarian Most cancers. He’ll focus on how Aspira’s soon-to-be-launched OVAWatchTM multivariate index assay diagnostic danger evaluation might profit girls with pelvic plenty who usually are not deliberate for surgical procedure.
A reside query and reply session will comply with the ready shows. To register for the occasion, please click on right here.
Nicole E. Williams, MD, FACOG, FACS: A local of East St. Louis, IL, Dr. Williams developed an affinity for public service early in her life. She is a tireless advocate for girls’s well being points, particularly maternal points, and has efficiently lobbied Congress on behalf of her sufferers. Dr. Williams additionally travels the world extensively, educating and working on those that want it most in essentially the most far-flung locations. She has labored in Haiti, Guyana, Rwanda, Ghana, the Philippines, Mexico, and Cambodia, to call a couple of. For the previous 8 years, she has sat on the helm of a profitable Gynecology follow, The Gynecology Institute of Chicago, whose practitioners specialise in different and conventional drugs. Moreover, she is a member of American Mensa, the worldwide high-IQ society.
Gerard P. Reilly, MD: Dr. Reilly graduated from College of Cincinnati Medical Faculty 1988 and accomplished residency in Cincinnati at Bethesda Hospital 1992. Dr. Reilly stopped practising OB in October 2021 after 30 years and 4,500 infants however nonetheless has his GYN follow with excessive quantity of robotic and hysteroscopic procedures. Dr. Reilly helped provoke a brand new analysis arm in Axia in Fall 2021 and is now Director of Scientific Analysis and Innovation for Axia Girls’s Well being. He oversees analysis research in OH, KY, IN, PA, and NJ and at the moment has 9 energetic research throughout the Axia footprint. Dr. Reilly has been named a “Prime Physician” for OB/GYN in Cincinnati a number of occasions and in addition on the checklist of Greatest Medical doctors in America since 2017. He additionally served as President of Seven Hills WHC from 2010-2019.
Dr. Reilly has been concerned in medical analysis tasks since 2005. Dr. Reilly is at the moment the Chairman of the Scientific Analysis Committee for the US Girls’s Well being Alliance. He’s at the moment one of many lead investigators for the Aspira OVANEX Examine. Dr. Reilly will probably be an investigator for EndoCheck and was lead creator on the article lately printed in JCO concerning the OvaNex neuronetwork lab.
About Aspira Girls’s Well being Inc.
Aspira Girls’s Well being Inc. is remodeling girls’s well being with the invention, growth, and commercialization of progressive testing choices and bio-analytical options that assist physicians assess danger, optimize affected person administration, and enhance gynecologic well being outcomes for girls. Aspira Girls’s Well being is especially centered on closing the ethnic disparity hole in ovarian most cancers danger evaluation and creating options for pelvic ailments akin to pelvic mass danger evaluation and endometriosis. OVA1plusTM combines our FDA-cleared merchandise, OVA1® and OVERA®, to detect danger of ovarian malignancy in girls with adnexal plenty. Aspira GenetiXTM testing presents each focused and complete genetic testing choices with a gynecologic focus. With over 10 years of experience in ovarian most cancers danger evaluation, Aspira Girls’s Well being is working to ship a portfolio of pelvic mass merchandise over a affected person’s lifetime with our cutting-edge analysis. The following technology of merchandise in growth embrace OVAWatchTM and EndoCheckTM. To enhance affected person accessibility, Aspira Girls’s Well being has lately launched our Aspira SynergyTM know-how switch platform to empower well being methods, lecturers, regional labs, and doctor group labs to conduct genetic and specialty exams in-house. Go to our web site for extra info at www.aspirawh.com.
This press launch comprises forward-looking statements, as outlined within the Personal Securities Litigation Reform Act of 1995, together with statements relating to, with out limitation, the Firm’s plans, forecasts, projections, potential growth and focus, present and future check choices. These statements contain quite a few dangers and uncertainties. All statements apart from statements of historic info contained on this press launch are forward-looking statements. Phrases akin to “might,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “might,” “ought to,” “proceed,” “will,” “potential,” “tasks” and related expressions are meant to determine forward-looking statements. These forward-looking statements communicate solely as of the date of this press launch and are topic to quite a few dangers, uncertainties, and assumptions, together with the dangers and uncertainties described within the part entitled “Threat Components” in Aspira Girls’s Well being’s Annual Report on Type 10Q, dated Might 11, 2022. The occasions and circumstances mirrored in Aspira Girls’s Well being’s forward-looking statements might not be achieved or happen and precise outcomes might differ materially from these projected within the forward-looking statements. Aspira Girls’s Well being expressly disclaims any obligation to replace, amend or make clear any forward-looking statements to mirror occasions, new info or circumstances occurring after the date of this press launch, besides as required by regulation.
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
E mail: [email protected]